Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03099603
Other study ID # 1801.PCT002
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date March 24, 2017
Est. completion date October 3, 2017

Study information

Verified date July 2020
Source HighTide Biopharma Pty Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, double blind, single center, ascending single dose study to evaluate the safety, tolerability, and PK of HTD1801.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date October 3, 2017
Est. primary completion date July 11, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

1. Age =18 to = 50 years

2. Body mass index (BMI) =18.0 to = 30.0 kg/m2

3. Current non-user of any nicotine containing products (>6 months)

4. Females must be non-pregnant and non-lactating, and either surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or post-menopausal for =12 months. The site will try to retrieve medical records to document the sterility, however, the absence of records will not exclude screening the participant. If medical records cannot be obtained, serum and urine pregnancy testing will be conducted. Postmenopausal status will be confirmed through testing of FSH levels = 40 IU/mL at screening for amenorrheic female participants <50 years of age.

Males must be surgically sterile (>30 days since vasectomy with no viable sperm), abstinent or if engaged in sexual relations with a child-bearing potential, the participant and his partner must be using an acceptable, highly effective, contraceptive method from Screening and for a period of 60 days after the last dose of Study Drug. Acceptable methods of contraception are the use of condoms and an effective contraceptive for the female partner that includes: surgical sterilization (e.g., bilateral tubal ligation), hormonal contraception, or intrauterine contraception/device). The Principal Investigator will assess the adequacy of methods of contraception on a case-by-case basis.

5. Ability to provide written informed consent.

Exclusion Criteria:

1. Participation in an investigational drug study within 30 days prior to dosing or 5 half-lives within the last dose of investigational product whichever is longer.

2. Current use of any prescription or over-the-counter (OTC) medications, including herbal products and supplements, within 14 days prior to Day 1 or 5 half-lives, whichever is longer. [Use of =2 g per day of paracetamol (acetaminophen) is allowed prior to and during the study at Investigator discretion. The reason for use must be listed either in the subject's baseline information or as an adverse event.]

3. Any use of non-steroid anti-inflammatory drugs (NSAIDs) within 7 days prior to dosing.

4. History of any serious adverse reaction or hypersensitivity to any of the product components.

5. Use of parenterally administered proteins or antibodies within 12 weeks of screening. (Note: Influenza vaccine will be allowed)

6. Glucose-6-phosphate dehydrogenase(G6PD) deficiency.

7. History of weight loss > 5% in the 8 weeks prior to screening.

8. History of any active infection, other than mild viral illness, within 30 days prior to dosing.

9. History of alcohol or illicit drug abuse as judged by the Investigator within approximately 1 year

10. Use of any nicotine-containing product within 6 months prior to Screening or at any time during the study and follow-up as confirmed by urine cotinine screening.

11. Presence of clinically significant medical history, physical, laboratory, or ECG findings that, in the opinion of the Investigator, may potentially compromise the safety of the subject, or interfere with any aspect of study conduct or interpretation of results.

Study Design


Intervention

Drug:
HTD1801
A small molecular compound for the treatment of primary sclerosing cholangitis

Locations

Country Name City State
Australia Nucleus Network Limited Melbourne Victoria

Sponsors (1)

Lead Sponsor Collaborator
HighTide Biopharma Pty Ltd

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants that experience Adverse Events (AEs) and Serious Adverse Events (SAEs) after single dose Incidence, severity and causality of AEs and SAEs up to Day 30
Secondary HTD1801 plasma concentration levels after single dose Concentration-Time data 96 hours
Secondary Pharmacokinetics (PK) of HTD1801 in plasma after single dose - peak plasma concentration (Cmax) PK parameters: Cmax 96 hours
Secondary PK of HTD1801 in plasma after single dose - area under the plasma concentration vs. time curve (AUC) PK parameters: AUC 96 hours
Secondary PK of HTD1801 in plasma after single dose - time to peak plasma concentration (Tmax) PK parameters: Tmax 96 hours
Secondary PK of HTD1801 in plasma after single dose - half life (T1/2) PK parameters: T1/2 96 hours
See also
  Status Clinical Trial Phase
Completed NCT02239211 - A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis Phase 2
Withdrawn NCT03216876 - A Study Of Ursolic Acid For Primary Sclerosing Cholangitis Phase 1
Recruiting NCT02605213 - Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients Phase 4
Recruiting NCT01688024 - Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis Phase 2
Completed NCT03041662 - Surveillance Study for Early Detection of Cholangiocarcinoma (CCA) in Primary Sclerosing Cholangitis (PSC)
Completed NCT05866809 - Evaluation of the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis Phase 2
Recruiting NCT05618145 - National Database on Primary Sclerosing Cholangitis (PSC)
Active, not recruiting NCT02446665 - Disease Status in Primary Sclerosing Cholangitis by Elastography N/A
Completed NCT02247934 - Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC) N/A
Completed NCT01088607 - Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis Phase 1
Terminated NCT01142323 - Pilot Study of Fenofibrate for PSC Phase 1/Phase 2
Terminated NCT04060147 - Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis Phase 1
Recruiting NCT04133792 - Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC) Phase 3
Active, not recruiting NCT04595825 - CM-101 in PSC Patients -The SPRING Study Phase 2
Recruiting NCT03183570 - Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT Early Phase 1
Completed NCT02943460 - Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis Phase 2
Completed NCT00951327 - Cholangioscopy Using Narrow Band Imaging (NBI) in Patients With Primary Sclerosing Cholangitis (PSC) Undergoing Endoscopic Retrograde Cholangiopancreatogram (ERCP) N/A
Completed NCT04024813 - A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC Phase 2
Recruiting NCT05912387 - Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study Early Phase 1
Completed NCT02884557 - NKT Role in the Regulation of the Inflammatory Bowel Disease N/A